L3VLUP
ProSign in

RYTM · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RYTMVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RYTM
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterRYTMVRTX
Q3 20201 holders, $95m31 holders, $21.9bn
Q4 20201 holders, $134m30 holders, $18.4bn
Q1 20211 holders, $87m31 holders, $15.4bn
Q2 20211 holders, $77m30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 20211 holders, $593k28 holders, $12.4bn
Q1 20221 holders, $474k23 holders, $16.1bn
Q2 20221 holders, $628k25 holders, $18.1bn
Q3 20222 holders, $43m22 holders, $18.4bn
Q4 20221 holders, $36m28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 20233 holders, $33m33 holders, $24.3bn
Q4 20234 holders, $61m32 holders, $28.6bn
Q1 20243 holders, $40m31 holders, $29.8bn
Q2 20244 holders, $32m29 holders, $33.4bn
Q3 20246 holders, $80m27 holders, $33.5bn
Q4 20244 holders, $131m26 holders, $28.5bn
Q1 20254 holders, $147m21 holders, $35.4bn
Q2 20255 holders, $160m21 holders, $32.3bn
Q3 20259 holders, $496m22 holders, $25.9bn
Q4 202510 holders, $537m26 holders, $31.8bn
Q1 20267 holders, $450m25 holders, $31.8bn
Q2 20269 holders, $859m26 holders, $34.6bn
RYTM

Rhythm Pharmaceuticals Inc

Holders
6
Reported value
$80m
Buyers
4
Sellers
3

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 29 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RYTM (2)

Caxton Associates LLP, PDT Partners LLC

Only VRTX (23)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →